Canaccord lowered the firm’s price target on AxoGen (AXGN) to $24 from $26 and keeps a Buy rating on the shares. The firm updated its model to reflect Q125 results and the subsequent 10Q release. As a reminder, the company reiterated FY25 revenue and gross margin guidance on its Q125 call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN: